Bio-Path calls in Acorn to help with siRNA drug trial

By Gareth Macdonald

- Last updated on GMT

Related tags Acute myeloid leukemia Pharmacology Clinical trial

Bio-Path Holdings has called in US CRO Acorn to provide a contract medical officer for a study of its candidate antisense cancer drug liposomal Grb-2.

Under the agreement, Bradley Somer will serve as Bio-Path’s Medical Officer and medical liaison for trials of liposomal Grb-2 in various forms of the disease including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Bio-Path CEO Peter Nielsen, said that: “As we prepare to enter a Phase I clinical trial for our lead liposomal antisense cancer drug, it is important that the company have access to service capabilities needed for the conduct of the trial​.”

Dr. Somer is an excellent fit to perform as Bio-Path’s Medical Officer in our Phase I clinical trial. His extensive experience in hematology and conduct of clinical trials in CML for large pharmaceutical companies will allow him to play a significant role in Bio-Path’s clinical trial.”

Bio-Path has the option of extending the deal to include more trial support, including project management, clinical data management, statistical analysis, medical and scientific writing as well as support services.

Liposomal delivery may be way forward for siRNA

Texan firm Bio-Path is developing leading edge, patented, liposomal drug delivery systems at the University of Texas. Anderson Cancer Center with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development.

Bio-Path’s technology distributes nucleic acid drugs systemically, throughout the human body, via intravenous infusion, and can be applied both to double stranded and single stranded nucleic acid compounds.

Related news

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more